Lisata Therapeutics Inc(LSTA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 6 at 4:00 PM ET (Korea 11/7 06:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.64 | Insider Own | 24.53% | Shs Outstand | 9.1M | Perf Week | 0.98% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 8.2M | Perf Month | -14.17% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 11.06% | Short Float | 0.35% | Perf Quarter | -5.5% |
| Income | -0.01B | P/S | 111.26 | EPS this Y | - | Inst Trans | -5.01% | Short Ratio | 0.1 | Perf Half Y | -67.3% |
| Sales | 0.00B | P/B | 1.14 | EPS next 5Y | - | ROA | -80.81% | Short Interest | 0.03M | Perf YTD | -44.62% |
| Book/sh | 0.9 | P/C | 1.07 | EPS past 3/5Y | 43.29% 24.76% | ROE | -99.89% | 52W High | -79.68% ($5.07) | Perf Year | -56.17% |
| Cash/sh | 0.97 | P/FCF | - | Sales past 3/5Y | - | ROIC | -177.35% | 52W Low | 7.25% ($0.96) | Perf 3Y | -54.82% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 26.48% | Gross Margin | 36% | Volatility(W/M) | 8.37% 9.1% | Perf 5Y | -93.92% |
| Dividend TTM | - | EV/Sales | 4.36 | Sales Y/Y TTM | -90.65% | Oper. Margin | -16427% | ATR (14) | 0.11 | Perf 10Y | -98% |
| Dividend Ex-Date | - | Quick Ratio | 3.69 | EPS Q/Q | 40.58% | Profit Margin | -14621% | RSI (14) | 42.46 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.69 | Sales Q/Q | -100% | SMA20 | -0.45% ($1.03) | Beta | 1.01 | Target Price | $4 |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -22.17% ($1.32) | Rel Volume | 0.05 | Prev Close | $0.99 |
| Employees | 21 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -45.1% - | SMA200 | -65.02% ($2.94) | Avg Volume(3M) | 0.28M | Price | $1.03 |
| IPO | 1995/11/3 | Option/Short | No/Yes | Trades | 251 | Volume | 15,114 | Change | 3.88% |
💉 This biotech company develops a drug that helps anticancer agents penetrate deeper into tumors. Its core technology, the CendR platform, modifies the tumor microenvironment to enhance the effectiveness of existing anticancer drugs. The lead candidate, certepetide, is currently in Phase 2 clinical trials for solid tumors such as pancreatic cancer and bile duct cancer.
Over the past 1 year, on the lower side
80% below its 1-year high.
Traded less than usual. That is 5% of its average volume.
LSTA has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $11,126. Peers typically go for $917.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -93.9%. The S&P 500 did +57% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 11.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #498 of 597 in the industry
Based on market cap of $11M.
BIVI#495 BioVie Inc $11M PER - 
PBM#496 Psyence Biomedical Ltd $11M PER - 
PTN#497 Palatin Technologies Inc $11M PER - LSTA#498 Lisata Therapeutics Inc $11M PER - 
HIND#499 Vyome Holdings Inc $11M PER - 
FAQ
What kind of company is LSTA?
LSTA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of LSTA?
The market cap of LSTA is approximately $11M, ranking 5,384 within its sector.
What is the 52-week high and low for LSTA?
LSTA has recorded a 52-week high of $5.07 and a low of $0.96.
